HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

J. Biol. Chem., Vol. 282, Issue 37, 26767-26774, September 14, 2007

This Article Full Text Full Text (PDF) All Versions of this Article: 282/37/26767    most recent M700440200v1 Submit a Letter to Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Begley, L. A. Articles by Macoska, J. A. Search for Related Content PubMed PubMed Citation Articles by Begley, L. A. Articles by Macoska, J. A. Social Bookmarking                      What's this?

CXCL12 Activates a Robust Transcriptional Response in Human Prostate Epithelial Cells^*

From the Department of Urology and the Comprehensive Cancer Center, University of Michigan, Ann Arbor, Michigan 48109

CXCL12 is a CXC-type chemokine that plays important roles in hematopoiesis, development, and organization of the immune system and supports the survival or growth of a variety of normal or malignant cell types. Our laboratory recently showed that CXCL12 is secreted by aging stromal fibroblast cells and is a major paracrine factor that specifically stimulates the proliferation of prostate epithelial cells. The current study shows that this CXCL12-mediated proliferative response may be either ERK-dependent or ERK-independent. Moreover, CXCL12 initiates a previously undefined and complex global transcriptional response in prostate epithelial cells. This CXCL12-mediated transcriptional response directly stimulates the expression of genes encoding proteins that are involved in the promotion of cellular proliferation and progression through the cell cycle, tumor metastasis, and cellular motility, and directly represses the transcription of genes encoding proteins involved in cell-cell adhesion and resistance to apoptosis. Thus, CXCL12 may play a major role in the etiology of benign proliferative disease in the context of an aging tissue microenvironment.

Received for publication, January 16, 2007 , and in revised form, July 12, 2007.

^* This work was supported by NIDDK/National Institutes of Health Award 1 P50 DK065313 from the George M. O'Brien Center for Urologic Research at the University of Michigan (to J. A. M.), UMCCC Support Grant 5 P30 CA46592, and funds awarded by Domino's Pizza, L.L.C. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

¹ To whom correspondence should be addressed: Dept. of Urology, The University of Michigan, 6217 Cancer Center and Geriatrics Center, 1500 East Medical Center Dr., Ann Arbor, MI 48109-0944. Tel.: 734-647-8121; Fax: 734-647-9271; E-mail: jcoska{at}umich.edu.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				J. Wang, Y. Shiozawa, J. Wang, Y. Wang, Y. Jung, K. J. Pienta, R. Mehra, R. Loberg, and R. S. Taichman The Role of CXCR7/RDC1 as a Chemokine Receptor for CXCL12/SDF-1 in Prostate Cancer J. Biol. Chem., February 15, 2008; 283(7): 4283 - 4294. [Abstract] [Full Text] [PDF]